Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria

NCT02392624 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT02392624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02392624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Completed
Start date
May 18, 2015
Completion date
March 9, 2017
Enrollment
206 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

urticaria